Advertisement
Advertisement


The Body PRO Covers: The 39th Annual Meeting of the Infectious Diseases Society of America

HIV/AIDS: Antiretroviral Therapy (Poster Session 87)

October 27, 2001

  • Final Results of a Pilot, 48-Week Study of Amprenavir/Abacavir/Lamivudine (APV/ABC/3TC) in ART-Naive Subjects with HIV-1 Infection (COL30309) (Poster 696)
    Authored by M. Dube, Indiana University, Indianapolis, IN; J. Hernandez, GlaxoSmithKline, Research Triangle Park, NC; H. Edmondson-Melancon, University of Southern CA, Los Angeles, CA; J.W. Fleming, T. Cates, GlaxoSmithKline, Research Triangle Park, NC; F. Sattler, University of Southern CA, Los Angeles, CA; V. Williams, D. Goodwin, GlaxoSmithKline, Research Triangle Park, NC


This is a good study of an AZT-less regimen. The combination of ABC and 3TC for the nucleosides is combined with amprenavir for the protease inhibitor. This could also be a regimen that is very unlikely to cause lipdystrophy or mitochondrial toxicity. Only one patient had the classic abacavir hypersensitivity reaction. Patients were naive to antiretrovirals and there was a good drop in HIV viral load and a rise of 170 in CD4 cells over 48 weeks. Basically, this regimen is as good as any NRTI/PI regimen with 69% of patients having <400 copies at 48 weeks. According to the authors, APV/RTV trials are underway to make this an easier-to-take regimen.


Previous | Next


This article was provided by TheBodyPRO.com. It is a part of the publication 39th Annual Meeting of the Infectious Diseases Society of America.
 



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
Advertisement